Changes in Clinical Control of COPD Patients Measured by the Clinical COPD Questionnaire During Therapy With Spiolto Respimat in Routine Clinical Practice
Phase of Trial: Phase IV
Latest Information Update: 26 Nov 2019
Price : $35 *
At a glance
- Drugs Olodaterol/tiotropium bromide (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim
- 22 Nov 2019 Planned End Date changed from 31 Aug 2019 to 4 Oct 2019.
- 22 Nov 2019 Planned primary completion date changed from 31 Aug 2019 to 4 Oct 2019.
- 02 Oct 2019 Status changed from active, no longer recruiting to completed.